AnHeart Therapeutics
Shuanglian (Lian) Li, M.D., Ph.D., is Senior Vice President and Chief Medical Officer (US) at AnHeart Therapeutics. In this role, Dr. Li will oversee and direct all U.S.-based clinical programs. Dr. Li is an accomplished clinical development physician with over 15 years of drug development experience from preclinical drug safety to late-stage drug development and post-marketing clinical research. Her clinical development expertise has specialized in precision medicine and adoptive cellular therapy.
Prior to joining AnHeart, Dr. Li was SVP of Clinical Development at Ansun Biopharma, where she led and drove the overall clinical development strategy of the company’s oncology pipeline and clinical development plan. She also led clinical and regulatory strategy as Head of Clinical Development at Skyline Therapeutics, a gene therapy company headquartered in Shanghai.
Dr. Li was also the Global Clinical Lead for mobocertinib, a first-in-class EGFR inhibitor that targeted EGFR exon 20 insertions, at Takeda Pharmaceuticals. Prior to its acquisition by Takeda, Dr. Li was Medical Director at ARIAD Pharmaceuticals and the medical lead for several oncology programs. Dr. Li has held various positions with increasing responsibilities at Biogen, Pfizer, and Sugen.
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.